
Childhood onset or late onset severe growth hormone deficiency (GH) Program in Pharmaceutical Benefits Scheme (PBS) 012-18112104

-   Background
-   Process
-   Resources

[Expand/Collapse all sections]Expand all

This document outlines details of PBS-subsidised somatropin for patients
with childhood onset or late onset of severe growth hormone (GH)
deficiency.

Severe GH deficiency and listing dates

Severe GH deficiency is a condition where the body is unable to produce
enough hormone which impairs the growth and development of adults.

Listing date:

-   somatropin - 1 December 2018

See Written Authority Required Drugs for more information

Treatment specifics

Somatropin is not a PBS-subsidised drug for patients with Prader-Willi
Syndrome aged 18 years or older without a documented childhood-onset
Growth Hormone Deficiency.

Enquiries

Transfer enquiries about prescription arrangements to the PBS Complex
Drugs Programs team and choose the option relevant to the condition
treated.

The Resources page contains links to application forms, contact details,
item and restriction codes, the PBS schedule and the Services Australia
website.

Related links

Online Pharmaceutical Benefits Scheme (PBS) Authorities System (OPA
System)

Process telephone authority approval application

Processing and National Demand Allocation (PaNDA)

Processing Written Authority Approval Request

Processing Written Authority Required Listings

Written Authority Required Drugs

                                   

-   Services Australia ABN 90 794 605 008 
